RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.

Proc Natl Acad Sci U S A 2011 Feb 2;108(8):3336-41. Epub 2011 Feb 2.

Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104-4318, USA.

Neuroblastoma is a childhood cancer that is often fatal despite intense multimodality therapy. In an effort to identify therapeutic targets for this disease, we performed a comprehensive loss-of-function screen of the protein kinome. Thirty kinases showed significant cellular cytotoxicity when depleted, with loss of the cell cycle checkpoint kinase 1 (CHK1/CHEK1) being the most potent. CHK1 mRNA expression was higher in MYC-Neuroblastoma-related (MYCN)-amplified (P < 0.0001) and high-risk (P = 0.03) tumors. Western blotting revealed that CHK1 was constitutively phosphorylated at the ataxia telangiectasia response kinase target site Ser345 and the autophosphorylation site Ser296 in neuroblastoma cell lines. This pattern was also seen in six of eight high-risk primary tumors but not in control nonneuroblastoma cell lines or in seven of eight low-risk primary tumors. Neuroblastoma cells were sensitive to the two CHK1 inhibitors SB21807 and TCS2312, with median IC(50) values of 564 nM and 548 nM, respectively. In contrast, the control lines had high micromolar IC(50) values, indicating a strong correlation between CHK1 phosphorylation and CHK1 inhibitor sensitivity (P = 0.0004). Furthermore, cell cycle analysis revealed that CHK1 inhibition in neuroblastoma cells caused apoptosis during S-phase, consistent with its role in replication fork progression. CHK1 inhibitor sensitivity correlated with total MYC(N) protein levels, and inducing MYCN in retinal pigmented epithelial cells resulted in CHK1 phosphorylation, which caused growth inhibition when inhibited. These data show the power of a functional RNAi screen to identify tractable therapeutical targets in neuroblastoma and support CHK1 inhibition strategies in this disease.

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1012351108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044382PMC
February 2011
31 Reads

Publication Analysis

Top Keywords

chk1
10
primary tumors
8
chk1 phosphorylation
8
neuroblastoma cells
8
cell lines
8
inhibitor sensitivity
8
cell cycle
8
revealed chk1
8
chk1 inhibition
8
checkpoint kinase
8
chk1 inhibitor
8
protein kinome
8
rnai screen
8
screen protein
8
ic50 values
8
neuroblastoma
6
inhibition neuroblastoma
4
phosphorylated ataxia
4
chk1 constitutively
4
constitutively phosphorylated
4

Altmetric Statistics

References

(Supplied by CrossRef)

Maris et al.
New England Journal of Medicine 2010

Matthay et al.
European journal of cancer (Oxford, England : 1990) 1995

Mosse et al.
Nature; Physical Science (London) 2008

George et al.
Nature; Physical Science (London) 2008

PNAS 2009

Molenaar et al.
Cancer Research 2008

Otto et al.
Cancer cell 2009

Chen et al.
Molecular Cancer Therapeutics 2003

Petermann et al.
Cell cycle (Georgetown, Tex.) 2006

Toledo et al.
Genes & Development 2008

Sanchez et al.
Science 1997

Similar Publications